Call +44 (0)1904 798634 or +44 (0)7550 079918

Leading provider of life science market reports and research services

Hemostats - Medical Devices Pipeline Assessment, 2016

Be the first to review this product

Hemostats - Medical Devices Pipeline Assessment, 2016

Summary

GlobalData's Medical Devices sector report, 'Hemostats - Medical Devices Pipeline Assessment, 2016' provides an overview of Hemostats...
You can choose to pay by purchase order during checkout

Availability: In stock

$4,000.00

* Required Fields

You can choose to pay by purchase order during checkout
GlobalData.

Digital downloads direct to your inbox within 24 hours.

First class customer service from our team of experts.

Pay by credit card or request an invoice

Product Description

Details

Hemostats - Medical Devices Pipeline Assessment, 2016

Summary

GlobalData's Medical Devices sector report, 'Hemostats - Medical Devices Pipeline Assessment, 2016' provides an overview of Hemostats currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Hemostats pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Hemostats under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Hemostats and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry

Reasons to buy

The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Hemostats under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product's current stage of development, territory and estimated launch date

Additional Information

Additional Information

Publisher name GlobalData.
Format PDF
Page count 118
Publication date 11 Mar 2016
Table of contents 1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 8
2 Introduction 9
2.1 Hemostats Overview 9
3 Products under Development 10
3.1 Hemostats - Pipeline Products by Stage of Development 10
3.2 Hemostats - Pipeline Products by Segment 11
3.3 Hemostats - Pipeline Products by Territory 12
3.4 Hemostats - Pipeline Products by Regulatory Path 13
3.5 Hemostats - Pipeline Products by Estimated Approval Date 14
3.6 Hemostats - Ongoing Clinical Trials 15
4 Hemostats - Pipeline Products under Development by Companies 16
4.1 Hemostats Companies - Pipeline Products by Stage of Development 16
4.2 Hemostats - Pipeline Products by Stage of Development 18
5 Hemostats Companies and Product Overview 20
5.1 3-D Matrix, Ltd. Company Overview 20
5.1.1 3-D Matrix, Ltd. Pipeline Products & Ongoing Clinical Trials Overview 20
5.2 Advanced Medical Solutions Group plc Company Overview 23
5.2.1 Advanced Medical Solutions Group plc Pipeline Products & Ongoing Clinical Trials Overview 23
5.3 Anika Therapeutics, Inc. Company Overview 31
5.3.1 Anika Therapeutics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 31
5.4 Arch Therapeutics Inc. Company Overview 33
5.4.1 Arch Therapeutics Inc. Pipeline Products & Ongoing Clinical Trials Overview 33
5.5 Argon Medical Devices Inc. Company Overview 37
5.5.1 Argon Medical Devices Inc. Pipeline Products & Ongoing Clinical Trials Overview 37
5.6 Baxter International Inc. Company Overview 38
5.6.1 Baxter International Inc. Pipeline Products & Ongoing Clinical Trials Overview 38
5.7 Beth Israel Deaconess Medical Center, Inc. Company Overview 43
5.7.1 Beth Israel Deaconess Medical Center, Inc. Pipeline Products & Ongoing Clinical Trials Overview 43
5.8 Biomedica Management Corporation Company Overview 44
5.8.1 Biomedica Management Corporation Pipeline Products & Ongoing Clinical Trials Overview 44
5.9 Biom'Up SAS Company Overview 48
5.9.1 Biom'Up SAS Pipeline Products & Ongoing Clinical Trials Overview 48
5.10 Cellphire, Inc. Company Overview 49
5.10.1 Cellphire, Inc. Pipeline Products & Ongoing Clinical Trials Overview 49
5.11 Covalent Medical, Inc. (Inactive) Company Overview 52
5.11.1 Covalent Medical, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 52
5.12 Covalon Technologies Ltd. Company Overview 53
5.12.1 Covalon Technologies Ltd. Pipeline Products & Ongoing Clinical Trials Overview 53
5.13 CryoLife, Inc. Company Overview 56
5.13.1 CryoLife, Inc. Pipeline Products & Ongoing Clinical Trials Overview 56
5.14 Endomedix Incorporated Company Overview 60
5.14.1 Endomedix Incorporated Pipeline Products & Ongoing Clinical Trials Overview 60
5.15 Entegrion, Inc. Company Overview 62
5.15.1 Entegrion, Inc. Pipeline Products & Ongoing Clinical Trials Overview 62
5.16 Ethicon, Inc. Company Overview 63
5.16.1 Ethicon, Inc. Pipeline Products & Ongoing Clinical Trials Overview 63
5.17 Floralis S.A.S. Company Overview 64
5.17.1 Floralis S.A.S. Pipeline Products & Ongoing Clinical Trials Overview 64
5.18 Gamma Therapeutics, Inc. Company Overview 65
5.18.1 Gamma Therapeutics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 65
5.19 Haemostatix Limited Company Overview 66
5.19.1 Haemostatix Limited Pipeline Products & Ongoing Clinical Trials Overview 66
5.20 Hemostasis, LLC Company Overview 69
5.20.1 Hemostasis, LLC Pipeline Products & Ongoing Clinical Trials Overview 69
5.21 KeraNetics, LLC Company Overview 71
5.21.1 KeraNetics, LLC Pipeline Products & Ongoing Clinical Trials Overview 71
5.22 LifeBond Ltd. Company Overview 72
5.22.1 LifeBond Ltd. Pipeline Products & Ongoing Clinical Trials Overview 72
5.23 Remedium Technologies Inc. Company Overview 75
5.23.1 Remedium Technologies Inc. Pipeline Products & Ongoing Clinical Trials Overview 75
5.24 Rice University Company Overview 76
5.24.1 Rice University Pipeline Products & Ongoing Clinical Trials Overview 76
5.25 Samyang Biopharmaceuticals Corporation Company Overview 78
5.25.1 Samyang Biopharmaceuticals Corporation Pipeline Products & Ongoing Clinical Trials Overview 78
5.26 Sanofi Company Overview 80
5.26.1 Sanofi Pipeline Products & Ongoing Clinical Trials Overview 80
5.27 Sea Run Holdings Inc. Company Overview 82
5.27.1 Sea Run Holdings Inc. Pipeline Products & Ongoing Clinical Trials Overview 82
5.28 St Teresa Medical, Inc. Company Overview 83
5.28.1 St Teresa Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 83
5.29 Suneris Technologies, Inc. Company Overview 87
5.29.1 Suneris Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 87
5.30 The Medicines Company Company Overview 88
5.30.1 The Medicines Company Pipeline Products & Ongoing Clinical Trials Overview 88
5.31 Therus Corporation Company Overview 90
5.31.1 Therus Corporation Pipeline Products & Ongoing Clinical Trials Overview 90
5.32 Xcede Technologies, Inc. Company Overview 91
5.32.1 Xcede Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 91
6 Hemostats- Recent Developments 92
6.1 Feb 18, 2016: Genelife Enters into Licensing Agreement with 3-D Matrix Europe 92
6.2 Feb 17, 2016: Z-Medica Receives Expanded CE Mark for QuikClot 92
6.3 Jan 21, 2016: United Health Products Announces Optimal Government Services as UHP's Exclusive Government Distributor 92
6.4 Dec 16, 2015: Arch Therapeutics Receives Clearance to Initiate Clinical Trial in Europe 93
6.5 Dec 09, 2015: Arsenal Medical Secures Funding from U.S. Army to Advance ResQFoam Trauma Product through Regulatory Approval 93
6.6 Dec 04, 2015: Change in B. Braun Management Board 94
6.7 Dec 01, 2015: Arch Therapeutics Reports Significant Wound Healing Results in Pre-Clinical Safety Study with AC5 Surgical Hemostatic Device 94
6.8 Nov 17, 2015: CryoLife Announces Resolution of PerClot Litigation with Medafor 95
6.9 Oct 28, 2015: United Health Products' HemoStyp Now Available Through Henry Schein 95
6.10 Oct 22, 2015: CoAg Medical And Lou Ferrigno Announce StopsBleeding Product Launch 95
6.11 Oct 20, 2015: Vascular Solutions Reports Third Quarter Results-2015 96
6.12 Sep 08, 2015: Arch Therapeutics Obtains Additional Positive Safety Data for AC5 Surgical Hemostatic Device in Preclinical Toxicity Test of Sensitization 98
6.13 Aug 24, 2015: United Health Products Announces School Health as a Distributor 99
6.14 Aug 18, 2015: Dynasil Announces Xcede Technologies' Patent Application for Novel All-in-One Patch 99
6.15 Aug 05, 2015: LifeBond Raises USD27 Million in Series D Financing 99
6.16 Aug 04, 2015: Suneris CEO to Present VETIGEL at White House Demo Day 99
6.17 Jul 21, 2015: Vascular Solutions Reports Second Quarter Results 100
6.18 Jul 15, 2015: Remedium Technologies Receives FDA Clearance for Hemogrip Technology to Help Stop Bleeding 102
6.19 Jul 14, 2015: St. Teresa Medical Announces First Patient Enrolled in SURGICLOT Clinical Trial in U.K 102
6.20 Jun 26, 2015: Suneris Introduces VETIGEL as a New Wound Care Solution for Veterinarians 103
6.21 Jun 15, 2015: OxySure Systems Enters into Distribution Agreement with Z-Medica 103
6.22 Jun 09, 2015: Arch Therapeutics Obtains Additional Safety Data for Its AC5 Surgical Hemostatic Device in Successful Preclinical Toxicity Test 103
6.23 May 13, 2015: DuBiotech Welcomes Germany's B.Braun 104
6.24 Apr 30, 2015: The Medicines Company Announces FDA Approval of RAPLIXA (Fibrin Sealant), the First and Only Powdered Fibrin Sealant Ready-to-Use for Mild to Moderate Surgical Bleeding 104
6.25 Apr 28, 2015: CryoLife Begins Patient Enrolment In PerClot IDE Clinical Trial 105
6.26 Apr 21, 2015: Vascular Solutions Reports First Quarter Results 106
6.27 Apr 16, 2015: Arch Therapeutics' AC5 Compared Favorably vs. Commercially Available Combination Hemostat in Animal Study 108
6.28 Apr 14, 2015: Arch Therapeutics Announces Favorable Preclinical Data From an Independent Study of AC5 Surgical Hemostatic Device Versus a Popular Fibrin Sealant 109
6.29 Apr 07, 2015: United Health Products Announces Laboratory Test Results 110
6.30 Apr 01, 2015: Z-Medica Announces QuikClot Products Approved in California 110
6.31 Mar 27, 2015: B. Braun Group increases sales and earnings 111
6.32 Mar 25, 2015: Arch Therapeutics Announces Favorable Preclinical Data from an Independent Study of AC5 Surgical Hemostatic Device Versus a Popular Cellulose-Based Hemostatic Agent 112
6.33 Mar 23, 2015: Arch Therapeutics Announces Positive Safety Results for AC5 Surgical Hemostatic Device in Preclinical Toxicity Studies 113
6.34 Mar 13, 2015: Withdrawal of Application for the Approval of the Hemostat (TDM-621) 113
6.35 Mar 12, 2015: CryoLife Provides Update on PerClot Litigation 113
7 Appendix 115
7.1 Methodology 115
7.2 About GlobalData 117
7.3 Contact Us 118
7.4 Disclaimer 118

Reviews

Write Your Own Review

Only registered users can write reviews. Please, log in or register

Product Tags

Product Tags

Use spaces to separate tags. Use single quotes (') for phrases.